Modulation of tumor-associated macrophage phenotype by S1P receptors
S1P 受体对肿瘤相关巨噬细胞表型的调节
基本信息
- 批准号:7970934
- 负责人:
- 金额:$ 5.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2012-09-29
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnimalsAnti-Inflammatory AgentsAnti-inflammatoryArterial Fatty StreakAtherosclerosisBiologicalBiological AssayBloodBlood VesselsCell LineCellsClinical ResearchCoculture TechniquesEnvironmentG-Protein-Coupled ReceptorsGrowth and Development functionImmuneImmune responseImmunomodulatorsIn VitroInflammatoryLaboratoriesLewis Lung CarcinomaLinkLipidsLysophospholipidsMalignant Epithelial CellMalignant neoplasm of ovaryMediatingModelingMono-SMononuclearMusNeoplasm MetastasisOvarian CarcinomaPeritoneumPhenotypeProductionProteinsRecruitment ActivityRegulationResearchRoleSignal TransductionSphingosine-1-Phosphate ReceptorSystemTestingToxic effectTumor AngiogenesisTumor ImmunityWomanangiogenesisarmcancer cellcell typechemokinecytokinecytotoxicityfeedingin vivomacrophagemigrationmonocytemouse modelneoplastic cellpolarized cellpublic health relevancereceptorresearch studyresponsesphingosine 1-phosphatetumortumor growthtumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Tumor development and growth are driven by tumor-supportive and pro-angiogenic molecules produced by cells recruited to the tumor microenvironment. Monocytes and macrophages (mono/MF) are believed to be recruited to the tumor as pro-inflammatory anti-tumor cells (M1) and then driven to an anti-inflammatory, pro-tumor phenotype (M2), which recruit more M2 cells. How this occurs in vivo is unclear, although in vitro studies indicate that the lipid sphingosine-1-phosphate (S1P) may affect MF phenotype. S1P utilizes five receptors, two of which (S1P1 and S1P2) are well-characterized immunomodulators and transduce opposing biological signals: S1P1 is characterized as anti-inflammatory and S1P2 as pro-inflammatory. Despite the implicated importance of S1P to MF phenotype in tumorigenesis, it is unknown how S1P directs phenotype decision and how S1P1 and 2 differentially affect this. Project Summary: The roles of S1P1 and 2 in mono/MF recruitment and phenotype decision, and the subsequent effect on MF-mediated tumor growth and angiogenesis will be clarified in vitro and in vivo using the ID8 mouse ovarian carcinoma cell line. The Specific Aims will: (1) clarify in vitro the contribution of S1P1 and 2 signaling to the modulation of TAM phenotype and (2) determine the differential contribution of S1P1 and 2 to TAM recruitment and phenotype in vivo. In vitro, how S1P1 or 2 signaling affect mono/MF phenotype will be assessed by examining protein markers and cellular responses in functional phenotype assays. Specific agonists and antagonists of S1P1 and 2 will be used and results confirmed with cells isolated from S1P1¿ or 2¿ mice. The roles of these receptors in MF migration and the support of tumorigenesis will be further delineated in vivo using the ID8 ovarian carcinoma model induced in WT, S1P1¿, or S1P2¿ animals. PUBLIC HEALTH RELEVANCE: Deciphering how S1P mediates the recruitment and activity of tumor-associated immune cells, such as TAMs, may offer new avenues of treatment for the induction of anti-tumor immunity by switching TAMs to an anti-tumor cell type. This would both down-regulate tumor-supportive activity and up-regulate other arms of the anti-tumor immune response, leading to more effective anti-tumor therapies.
描述(由申请方提供):肿瘤发育和生长由募集至肿瘤微环境的细胞产生的肿瘤支持和促血管生成分子驱动。 单核细胞和巨噬细胞(mono/MF)被认为是作为促炎性抗肿瘤细胞(M1)被募集到肿瘤中,然后被驱动为抗炎性促肿瘤表型(M2),其募集更多的M2细胞。 这在体内如何发生尚不清楚,尽管体外研究表明脂质鞘氨醇-1-磷酸(S1 P)可能影响MF表型。 S1 P利用五种受体,其中两种(S1 P1和S1 P2)是充分表征的免疫调节剂,并抑制相反的生物信号:S1 P1被表征为抗炎,S1 P2被表征为促炎。 尽管S1 P对MF表型在肿瘤发生中的重要性,但尚不清楚S1 P如何指导表型决定以及S1 P1和2如何差异化地影响这一点。 项目概要:S1 P1和2在单/MF招募和表型决定中的作用,以及随后对MF介导的肿瘤生长和血管生成的影响将在体外和体内使用ID 8小鼠卵巢癌细胞系进行澄清。 具体目标将:(1)阐明体外S1 P1和2信号传导对TAM表型调节的贡献和(2)确定体内S1 P1和2对TAM募集和表型的差异贡献。 在体外,S1 P1或2信号传导如何影响mono/MF表型将通过检查功能表型测定中的蛋白质标志物和细胞应答来评估。 将使用S1 P1和2的特异性激动剂和拮抗剂,并使用从S1 P1 ½或2 ½小鼠分离的细胞确认结果。 这些受体在MF迁移和支持肿瘤发生中的作用将使用在WT、S1 P1 <$或S1 P2 <$动物中诱导的ID 8卵巢癌模型在体内进一步描述。 公共卫生关系:破译S1 P如何介导肿瘤相关免疫细胞(如TAM)的募集和活性,可能为通过将TAM转换为抗肿瘤细胞类型来诱导抗肿瘤免疫提供新的治疗途径。 这将下调肿瘤支持活性并上调抗肿瘤免疫应答的其他分支,从而导致更有效的抗肿瘤疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Victoria Alison Blaho其他文献
Victoria Alison Blaho的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Victoria Alison Blaho', 18)}}的其他基金
Mechanisms of hematopoietic acute radiation syndrome induction and radioprotection through sphingosine 1-phosphate receptor 1 signal modulation
鞘氨醇1-磷酸受体1信号调节诱导造血急性辐射综合征和辐射防护的机制
- 批准号:
10438828 - 财政年份:2018
- 资助金额:
$ 5.22万 - 项目类别:
Mechanisms of hematopoietic acute radiation syndrome induction and radioprotection through sphingosine 1-phosphate receptor 1 signal modulation
鞘氨醇1-磷酸受体1信号调节诱导造血急性辐射综合征和辐射防护的机制
- 批准号:
10200131 - 财政年份:2018
- 资助金额:
$ 5.22万 - 项目类别:
Modulation of tumor-associated macrophage phenotype by S1P receptors
S1P 受体对肿瘤相关巨噬细胞表型的调节
- 批准号:
8119776 - 财政年份:2009
- 资助金额:
$ 5.22万 - 项目类别:
Modulation of tumor-associated macrophage phenotype by S1P receptors
S1P 受体对肿瘤相关巨噬细胞表型的调节
- 批准号:
7753317 - 财政年份:2009
- 资助金额:
$ 5.22万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 5.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 5.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 5.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)